MARKET

CRIS

CRIS

Curis
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.530
-0.050
-3.16%
Closed 18:50 12/12 EST
OPEN
1.570
PREV CLOSE
1.580
HIGH
1.630
LOW
1.490
VOLUME
226.15K
TURNOVER
--
52 WEEK HIGH
2.900
52 WEEK LOW
0.6200
MARKET CAP
50.80M
P/E (TTM)
-1.7212
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CRIS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CRIS News

  • Kinase inhibitors in focus after Merck bid for ArQule
  • seekingalpha.3d ago
  • The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling
  • Benzinga.5d ago
  • Curis up 8% premarket on encouraging CA-4948 in NHL
  • seekingalpha.6d ago
  • Curis Reports First Demonstration Of Targeting IRAK4 In Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma Results in Anti-Cancer Activity in Ongoing Phase 1 Study
  • Benzinga.6d ago

More

Industry

Biotechnology & Medical Research
+0.57%
Pharmaceuticals & Medical Research
+0.73%

Hot Stocks

Name
Price
%Change

About CRIS

Curis, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company's drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T-cell activation (VISTA) immune checkpoint proteins, both of which independently function as negative regulators of immune activation. CA-4948 is an oral small molecule drug candidate that is designed to inhibit the Interleukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is a transducer of toll-like receptor or certain interleukin receptor signaling pathways.
More

Webull offers Curis, Inc. (CRIS) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.